Levels of cotinine associated with long-term ad-libitum nicotine polacrilex use in a clinical trial

Murray, Robert P.; Nides, Mitchell; Istvan, Joseph A.; Daniels, Kathleen

doi:10.1016/s0306-4603(97)00073-7

Cited by 15 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lower nicotine levels are reached with NRT compared to smoking (i.e. the high peak plasma levels of nicotine reached during smoking are not achieved), which is the main reason why these products are not as effective as ''cigarettes'' regarding effects on craving and urge [17,18]. NRT products are used for 6-12 weeks as the abstinent smoker gradually reduces their daily dose in parallel with a decrease in withdrawal symptoms.…”

Section: Nicotine Replacement Therapymentioning

confidence: 99%

Smoking cessation and COPD

Tønnesen

2013

Eur Respir Rev

130

View full text Add to dashboard Cite

The mainstay in smoking cessation is counselling in combination with varenicline, nicotine replacement therapy (NRT) or bupropion SR. Varenicline and combination of two NRTs is equally effective, while varenicline alone is more effective than either NRT or bupropion SR. NRT is extremely safe but cardiovascular and psychiatric adverse events with varenicline have been reported. These treatments have also been shown to be effective in patients with chronic obstructive pulmonary disease (COPD).A model study is the Lung Health Study from the USA. Findings from this study of 5,587 patients with mild COPD showed that repeated smoking cessation for a period of 5 yrs resulted in a quit rate of 37%. After 14.5 yrs the quitters had a higher lung function and a higher survival rate. A study with a new nicotine formulation, a mouth spray, showed high relative efficacy. As 5-10% of quitters use long-term NRT, we report the results of a study where varenicline compared with placebo increased the quit rate in long-term users of NRT.Smoking cessation is the most effective intervention in stopping the progression of COPD, as well as increasing survival and reducing morbidity. This is why smoking cessation should be the top priority in the treatment of COPD.

show abstract

Section: Nicotine Replacement Therapymentioning

confidence: 99%

Smoking cessation and COPD

Tønnesen

2013

Eur Respir Rev

130

View full text Add to dashboard Cite

show abstract

“…For any individual participant in Lung Health Study 1, the duration of the study was 5 years. In Lung Health Study 1, participants were encouraged to use nicotine replacement therapy (Nicorette 2 mg, Marion Merrell Dow, Kansas City, MO) liberally for 6 months, although some continued to use nicotine replacement therapy well beyond that point ( Murray, Nides, Istvan, & Daniels, 1998 ). After 2.5 years, they were encouraged to cease using nicotine replacement therapy.…”

Section: Samplementioning

confidence: 99%

Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study

Murray¹,

Connett²,

Zapawa

2009

Nicotine & Tobacco Research

View full text Add to dashboard Cite

show abstract

“…Adverse effects indicative of overdose were not seen. Murray, Nides, Istvan, and Daniels, 1998. Patients with mild to moderate chronic obstructive pulmonary disease entered this smoking cessation study.…”

Section: Acute Dosing Systemsmentioning

confidence: 99%

Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: A review

Fagerström¹,

Hughes

2002

CNTR

View full text Add to dashboard Cite

This paper reviews the data on blood nicotine or saliva cotinine concentrations with concomitant smoking and use of nicotine replacement (NR) products. Eleven studies that provided data on blood nicotine concentrations, carbon monoxide in exhaled air, and number of cigarettes smoked were reviewed. At least one day had to be spent on concurrent use of cigarette and NR products. With simultaneous use of smoking and acute NR products (gum and inhaler) the nicotine concentrations were unchanged, whereas they increased (+54%) with nicotine patches. With both types of NR products, the number of cigarettes smoked per day was reduced by approximately 50% and carbon monoxide (CO) by 30%. Where smokers had the intention or received instructions to reduce smoking, a greater reduction in cigarettes smoked and exhaled CO was observed. Despite substantially increased nicotine concentrations (e.g., up to 3 times the approved dose) there were no significant adverse reactions. Concurrent use of NR products and cigarette smoking appears to be safe.

show abstract

Levels of cotinine associated with long-term ad-libitum nicotine polacrilex use in a clinical trial

Cited by 15 publications

References 10 publications

Smoking cessation and COPD

Smoking cessation and COPD

Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study

Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: A review

Contact Info

Product

Resources

About